Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ: COAG) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Hemab Therapeutics Holdings, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $39.06, Hemab Therapeutics Holdings, Inc. Common Stock trades at 4.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -73.6%, return on invested capital of -23.2% and a free cash flow yield of -4.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 33.86. Over the past 52 weeks the share price ranged from $23.00 to $55.42, with a beta of 1.85.
Hemab Therapeutics Holdings, Inc. Common Stock does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 33.9% / 30% · Interest income / Revenue 338400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 33.9% / 33% · Receivables / Mkt Cap (36m) 0.09% / 49% · Interest income / Revenue 338400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 33.9% / 33.33% · Receivables / Mkt Cap (24m) 0.09% / 33.33% · Interest income / Revenue 338400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.6% / 33.33% · Receivables / Avg Assets (4Q) 0.41% / 33.33% · Interest income / Revenue 338400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.2% / 33.33% · (Cash+Recv) / Total Assets 97.5% / 33.33% · Interest income / Revenue 338400000.0% / 5% | Fail |
No. As of September 2026, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Hemab Therapeutics Holdings, Inc. Common Stock is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 338400000.0% of each dividend: Hemab Therapeutics Holdings, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.